AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 287: E1100-E1106, 2004. First published August 3, 2004; doi:10.1152/ajpendo.00214.2004
0193-1849/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/6/E1100    most recent
00214.2004v2
00214.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agha, A.
Right arrow Articles by Thompson, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agha, A.
Right arrow Articles by Thompson, C. J.

Attenuation of vasopressin-induced antidiuresis in poorly controlled type 2 diabetes

Amar Agha,1 Diarmuid Smith,1 Francis Finucane,1 Mark Sherlock,1 Andrew Morris,2 Peter Baylis,3 and Christopher J. Thompson1

1Academic Department of Endocrinology, Beaumont Hospital, Dublin 9, Ireland; 2Division of Medicine and Therapeutics, Ninewells Hospital, Dundee DD1 9SY, Scotland; and 3Endocrine Unit, Royal Victoria Infirmary, Newcastle NEI 4LP, England

Submitted 21 May 2004 ; accepted in final form 30 July 2004

Renal resistance to vasopressin has been demonstrated in type 1 diabetes and in type 2 diabetes with nephropathy. However, renal response to vasopressin in type 2 diabetes without nephropathy has not been studied. We studied 10 subjects with poorly controlled type 2 diabetes (PCDS; Hb A1c >9%), 10 subjects with well-controlled type 2 diabetes (WCDS; Hb A1c <7%), and 10 matched nondiabetic control subjects (NDCS) during a euglycemic 8-h water deprivation test. None of the subjects had nephropathy. Water deprivation caused similar rises in plasma vasopressin concentrations in all three groups, but the rise in urine osmolality in PCDS (280.3 ± 49.7 to 594.4 ± 88.5 mosmol/kgH2O) was lower than in WCDS (360.7 ± 142.8 to 794.1 ± 77.3 mosmol/kgH2O, P < 0.001) or NDCS (336.0 ± 123.3 to 786.5 ± 63.3 mosmol/kgH2O, P = 0.019). Total urine output was higher in the PCDS than in WCDS and NDCS (P < 0.05). Linear regression analysis showed that, in PCDS, the osmotic thresholds for thirst (291.9 ± 4.6 mosmol/kgH2O) and vasopressin release (291.1 ± 2.9 mosmol/kgH2O) were higher compared with WCDS (286.6 ± 1.8 and 286.0 ± 3.6 mosmol/kgH2O, respectively) and NDCS (286.0 ± 2.4 and 284.1 ± 4.7 mosmol/kgH2O, respectively) (between groups P < 0.001 for both variables). Under conditions of euglycemia, PCDS have impaired renal response to vasopressin and elevated osmotic threshold for thirst and vasopressin release in response to dehydration. Under conditions of chronic hyperglycemia, these abnormalities may significantly contribute to the development of dehydration in PCDS.

osmoregulation



Address for reprint requests and other correspondence: C. Thompson, Endocrine Unit, Beaumont Hospital, Dublin 9, Ireland (E-mail: chris.thompson{at}beaumont.ie)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.